|
1
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Borst P, Jonkers J and Rottenberg S: What
makes tumors multidrug resistant? Cell Cycle. 6:2782–2787. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gillet JP, Calcagno AM, Varma S, Marino M,
Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al:
Redefining the relevance of established cancer cell lines to the
study of mechanisms of clinical anti-cancer drug resistance. Proc
Natl Acad Sci USA. 108:18708–18713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Correia AL and Bissell MJ: The tumor
microenvironment is a dominant force in multidrug resistance. Drug
Resist Updat. 15:39–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grinnell F, Rocha LB, Iucu C, Rhee S and
Jiang H: Nested collagen matrices: A new model to study migration
of human fibroblast populations in three dimensions. Exp Cell Res.
312:86–94. 2006.
|
|
6
|
Green JA and Yamada KM: Three-dimensional
microenvironments modulate fibroblast signaling responses. Adv Drug
Deliv Rev. 59:1293–1298. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Orimo A, Gupta PB, Sgroi DC,
Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL
and Weinberg RA: Stromal fibroblasts present in invasive human
breast carcinomas promote tumor growth and angiogenesis through
elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flach EH, Rebecca VW, Herlyn M, Smalley KS
and Anderson AR: Fibroblasts contribute to melanoma tumor growth
and drug resistance. Mol Pharm. 8:2039–2049. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cirri P and Chiarugi P:
Cancer-associated-fibroblasts and tumour cells: A diabolic liaison
driving cancer progression. Cancer Metastasis Rev. 31:195–208.
2012. View Article : Google Scholar
|
|
10
|
Dong J, Grunstein J, Tejada M, Peale F,
Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, et al:
VEGF-null cells require PDGFR alpha signaling-mediated stromal
fibroblast recruitment for tumorigenesis. EMBO J. 23:2800–2810.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Camps JL, Chang SM, Hsu TC, Freeman MR,
Hong SJ, Zhau He, von Eschenbach AC and Chung LW:
Fibroblast-mediated acceleration of human epithelial tumor growth
in vivo. Proc Natl Acad Sci USA. 87:75–79. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Folkman J: Tumor angiogenesis and tissue
factor. Nat Med. 2:167–168. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fallon JK, Neubert H, Hyland R, Goosen TC
and Smith PC: Targeted quantitative proteomics for the analysis of
14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with
selected reaction monitoring. J Proteome Res. 12:4402–4413. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Higgins JW, Bao JQ, Ke AB, Manro JR,
Fallon JK, Smith PC and Zamek-Gliszczynski MJ: Utility of
Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of
OATP-mediated pharmacokinetics and tissue distribution: Case
studies with pravastatin, atorvastatin, simvastatin, and
carboxydichlorofluorescein. Drug Metab Dispos. 42:182–192. 2014.
View Article : Google Scholar
|
|
15
|
Shin SI, Freedman VH, Risser R and Pollack
R: Tumorigenicity of virus-transformed cells in nude mice is
correlated specifically with anchorage independent growth in vitro.
Proc Natl Acad Sci USA. 72:4435–4439. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Colburn NH, Bruegge WF, Bates JR, gray RH,
Rossen JD, Kelsey WH and Shimada T: Correlation of
anchorage-independent growth with tumorigenicity of chemically
transformed mouse epidermal cells. Cancer Res. 38:624–634.
1978.PubMed/NCBI
|
|
17
|
Chung HC, Rha SY, Kim JH, Roh JK, Min JS,
Lee KS, Kim BS and Lee KB: P-glycoprotein: The intermediate end
point of drug response to induction chemotherapy in locally
advanced breast cancer. Breast Cancer Res Treat. 42:65–72. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hinz B, Celetta G, Tomasek JJ, Gabbiani G
and Chaponnier C: Alpha-smooth muscle actin expression upregulates
fibroblast contractile activity. Mol Biol Cell. 12:2730–2741. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ostman A and Augsten M: Cancer-associated
fibroblasts and tumor growth - bystanders turning into key players.
Curr Opin Genet Dev. 19:67–73. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishii G, Sangai T, Ito T, Hasebe T, Endoh
Y, Sasaki H, Harigaya K and Ochiai A: In vivo and in vitro
characterization of human fibroblasts recruited selectively into
human cancer stroma. Int J Cancer. 117:212–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Casazza AM and Fairchild CR: Paclitaxel
(Taxol): Mechanisms of resistance. Cancer Treat Res. 87:149–171.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davidson JD, Ma L, Flagella M, Geeganage
S, Gelbert LM and Slapak CA: An increase in the expression of
ribonucleotide reductase large subunit 1 is associated with
gemcitabine resistance in non-small cell lung cancer cell lines.
Cancer Res. 64:3761–3766. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bergman AM, Pinedo HM, Talianidis I,
Veerman G, Loves WJ, van der Wilt CL and Peters GJ: Increased
sensitivity to gemcitabine of P-glycoprotein and multidrug
resistance-associated protein-overexpressing human cancer cell
lines. Br J Cancer. 88:1963–1970. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yusuf RZ, Duan Z, Lamendola DE, Penson RT
and Seiden MV: Paclitaxel resistance: Molecular mechanisms and
pharmacologic manipulation. Curr Cancer Drug Targets. 3:1–19. 2003.
View Article : Google Scholar : PubMed/NCBI
|
